Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study.

MLA

van der Wall, Sake J., et al. “Low Bleeding and Thromboembolic Risk with Continued Dabigatran during Cardiovascular Interventions: The GLORIA-AF Study.” European Journal of Internal Medicine, vol. 91, Sept. 2021, pp. 75–80. EBSCOhost, https://doi.org/10.1016/j.ejim.2021.05.020.

APA

van der Wall, S. J., Lip, G. Y. H., Teutsch, C., Kalejs, O., Lyrer, P., Hall, C., Dubner, S. J., Diener, H.-C., Halperin, J. L., Ma, C. S., Rothman, K. J., Zint, K., Zhai, D., & Huisman, M. V. (2021). Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study. European Journal of Internal Medicine, 91, 75–80. https://doi.org/10.1016/j.ejim.2021.05.020

Chicago

van der Wall, Sake J, Gregory Y H Lip, Christine Teutsch, Oskars Kalejs, Philippe Lyrer, Christian Hall, Sergio J Dubner, et al. 2021. “Low Bleeding and Thromboembolic Risk with Continued Dabigatran during Cardiovascular Interventions: The GLORIA-AF Study.” European Journal of Internal Medicine 91 (September): 75–80. doi:10.1016/j.ejim.2021.05.020.